Actinium Pharmaceuticals, Inc. (ATNM) stock
Close on Nov 13, 2026Market cap $51.56MP/E 4.6Yield –
Actinium Pharmaceuticals, Inc. reported revenue of $90.00K for fiscal 2025. Free cash flow was -$24.68M. At the latest close the market valued the company at $51.56M, 4.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $51.56M
- P/E ratio
- 4.6
- Price to sales
- –
- Price to book
- 1.70
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $90.00K
- Net income
- $11.31M
- EPS, diluted
- $0.36
- Free cash flow
- -$24.68M
- Book value per share
- $0.96
- Diluted shares
- 31M
Trading
- Previous close
- $1.59
- Open
- $1.60
- Day's range
- $1.55 – $1.64
- Volume
- 180,622
- Average volume (20 days)
- 278,665
- Beta (5 years)
- 1.10
- 52-week range
- $0.74 – $1.72
- RSI (14 days)
- 65.3
- Volatility (1 year)
- 74.1%
- Relative volume
- 1.08×
- WACC
- 10.6%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATNM | S&P 500 | Difference | ATNM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +64.1% | -3.0% | +67.1 pts | ||
| 3 months | +70.1% | -2.8% | +72.9 pts | ||
| Year to date | +20.6% | +11.5% | +9.1 pts | ||
| 1 year | +31.2% | +13.5% | +17.7 pts | ||
| 3 years | -63.6% | +77.7% | −141.3 pts | -28.6% | +21.1% |
| 5 years | -79.4% | +72.6% | −152.0 pts | -27.1% | +11.5% |
| 10 years | -94.8% | +308.2% | −403.0 pts | -25.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Actinium Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- News
- Update
- Update
About Actinium Pharmaceuticals
Pharmaceutical Preparations
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer treatment. The company combines tumor biology and radiochemistry to advance radiopharmaceutical therapeutics for solid tumors and hematologic malignancies. Its pipeline includes solid tumor product candidates such as ATNM-400, an Ac-225 antibody radioconjugate targeting a non-PSMA antigen across indications such as prostate, non-small cell lung, and breast cancers, and Actimab-A, which targets CD33-positive myeloid-derived suppressor cells in combination with checkpoint inhibitors. In hematology, Actimab-A serves as a therapy for acute myeloid leukemia and myelodysplastic syndrome, while Iomab-B and Iomab-ACT are targeted conditioning agents for bone marrow transplants and cell and gene therapies. The company addresses patients suffering from various oncologic and hematologic conditions.
Company profile, executives and historyActinium Pharmaceuticals stock: common questions
What is Actinium Pharmaceuticals's stock price?
ATNM closed at $1.64 on Nov 13, 2026, up 3.14% on the day. Over the past 52 weeks it traded between $0.74 and $1.72.
What is Actinium Pharmaceuticals's market cap?
Actinium Pharmaceuticals was worth $51.56M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ATNM's P/E ratio?
ATNM trades at 4.6 times earnings, based on diluted earnings per share of $0.36 over the twelve months to Jun 30, 2026.
How much revenue does Actinium Pharmaceuticals make?
Actinium Pharmaceuticals reported revenue of $90.00K for fiscal 2025.
Does Actinium Pharmaceuticals pay a dividend?
No. Actinium Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has ATNM stock performed over the past year?
Including dividends, ATNM returned +31.2% over the past year, against +13.5% for the S&P 500.
How many ATNM shares are sold short?
1M shares were sold short at the latest FINRA report, 2.01% of the float, or 1.7 days of average trading volume.
Who are Actinium Pharmaceuticals's competitors?
Companies most similar to Actinium Pharmaceuticals by business, industry and size include LSTA, SNGX, IXHL, KZIA, HIND.
See a number that looks wrong?